We expect a decent Q1 2023 report on 12 May with fairly stable developments in all segments; we fore...
Redeye increases its Base Case and forecasts following a strong Q1 and a record high order book.
2% revenue beat; 20% EBIT beat driven by lower costs We take '23e EBIT up ~3% to the higher end of g...
Redeye noterar att konkurrenten Eli Lilly har presenterat positiv top-line data med Donanemab i fas ...
Exel’s Q1 was expected to be soft but it turned out quite weak.
Nya data underbygger effekten hos nadunolimab och det är fortsatt dröjsmål i PanCAN-studien.
Maven Wireless Sweden AB (”Maven” eller ”Koncernen”) har inlett året starkt där Q1-rapporten visade ...
God organisk omsättningsutveckling Beijer Alma redovisar ett starkt kvartal utifrån förväntningarna.
Fortsatt starkt på intäktssidan Corline levererade under torsdagen en stark rapport som var i linje ...
Odramatiska siffror Rapporten för det första kvartalet visade på fortsatt låg försäljning som uppgic...
Growth initiatives behind decision to replace CEO QRIOS slips into red as new CEO is hired Tough mar...
Aspo’s Q1 results were a bit lower than estimated. We find there to have been mixed development unde...
Redeye concludes that Railcare had a strong start to the year, both in terms of sales and earnings.
Q1: Sales 9% above, gross profit 1% above Reiterates '23 guidance: 20% y-o-y growth on midpoint Rece...
Taaleri reported Q1 EBIT of EUR 1.6m, coming 6% below Refinitiv consensus at EUR 1.
Redeye will likely increase its Base Case and forecasts following a strong Q1 report in line with pr...
Redeye provides a preview ahead of Fragbite Group’s Q1’2023e report, where we slightly lower our sal...
NOI +52% y-o-y, +4% vs ABGSCe No write-down of MFG, discussions are ongoing Another very solid opera...
Stable top line and solid NOI margin... ...coupled with prolonged interest maturity.
Ahead of NoHo Partners' Q1 report due on 9 May, we make only minor estimate revisions and note solid...
